1203 related articles for article (PubMed ID: 19406595)
1. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
2. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG-PET/CT of orofacial tumors, a value of whole-body imaging approach.
Ferda J; Ferdová E; Záhlava J; Walter J; Mukensnabl P; Daum O; Kreuzberg B
Eur J Radiol; 2010 Feb; 73(2):241-8. PubMed ID: 19101104
[TBL] [Abstract][Full Text] [Related]
4. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
[TBL] [Abstract][Full Text] [Related]
5. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
6. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
Chen Z; Li X; Li F; Ouyang Q; Yu T
Eur J Radiol; 2010 Sep; 75(3):329-35. PubMed ID: 20576385
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
8. PET and PET/CT in pediatric oncology.
Jadvar H; Connolly LP; Fahey FH; Shulkin BL
Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
[TBL] [Abstract][Full Text] [Related]
9. Monitoring cancer treatment with PET/CT: does it make a difference?
Weber WA; Figlin R
J Nucl Med; 2007 Jan; 48 Suppl 1():36S-44S. PubMed ID: 17204719
[TBL] [Abstract][Full Text] [Related]
10. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
11. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care.
Gordin A; Golz A; Keidar Z; Daitzchman M; Bar-Shalom R; Israel O
Otolaryngol Head Neck Surg; 2007 Jul; 137(1):130-7. PubMed ID: 17599580
[TBL] [Abstract][Full Text] [Related]
12. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
13. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
14. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma.
Quon A; Fischbein NJ; McDougall IR; Le QT; Loo BW; Pinto H; Kaplan MJ
J Nucl Med; 2007 Jan; 48 Suppl 1():58S-67S. PubMed ID: 17204721
[TBL] [Abstract][Full Text] [Related]
15. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
Israel O; Kuten A
J Nucl Med; 2007 Jan; 48 Suppl 1():28S-35S. PubMed ID: 17204718
[TBL] [Abstract][Full Text] [Related]
16. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
[TBL] [Abstract][Full Text] [Related]
17. Imaging in multiple myeloma.
Delorme S; Baur-Melnyk A
Eur J Radiol; 2009 Jun; 70(3):401-8. PubMed ID: 19272726
[TBL] [Abstract][Full Text] [Related]
18. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.
Czernin J; Allen-Auerbach M; Schelbert HR
J Nucl Med; 2007 Jan; 48 Suppl 1():78S-88S. PubMed ID: 17204723
[TBL] [Abstract][Full Text] [Related]
19. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
Saif MW; Cornfeld D; Modarresifar H; Ojha B
J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]